Cullinan Therapeutics Inc (CGEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -167,575 | -119,928 | -79,368 | -37,340 | -155,101 |
| Depreciation Amortization | 306 | 229 | 153 | 76 | 310 |
| Accounts payable and accrued liabilities | -812 | -378 | -938 | 1,214 | -167 |
| Other Working Capital | -389 | -5,210 | -7,052 | -5,904 | -339 |
| Other Operating Activity | 23,167 | 16,610 | 12,667 | 3,707 | 21,022 |
| Operating Cash Flow | $-145,303 | $-108,677 | $-74,538 | $-38,247 | $-134,275 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | N/A | -208 |
| Purchase Of Investment | -721,131 | -553,095 | -456,298 | -131,369 | -373,383 |
| Sale Of Investment | 584,817 | 400,817 | 284,142 | 144,325 | 409,397 |
| Investing Cash Flow | $-136,314 | $-152,278 | $-172,156 | $12,956 | $35,806 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 1,825 |
| Common Stock Issued | 270,636 | 269,054 | 267,073 | 1,085 | 38,926 |
| Other Financing Activity | -4,448 | -4,448 | -3,792 | 0 | 0 |
| Financing Cash Flow | $266,188 | $264,606 | $263,281 | $1,085 | $40,751 |
| Beginning Cash Position | 98,434 | 98,434 | 98,434 | 98,434 | 156,152 |
| End Cash Position | 83,005 | 102,085 | 115,021 | 74,228 | 98,434 |
| Net Cash Flow | $-15,429 | $3,651 | $16,587 | $-24,206 | $-57,718 |
| Free Cash Flow | |||||
| Operating Cash Flow | -145,303 | -108,677 | -74,538 | -38,247 | -134,275 |
| Capital Expenditure | N/A | N/A | N/A | N/A | -208 |
| Free Cash Flow | -145,303 | -108,677 | -74,538 | -38,247 | -134,483 |